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Dr. Jaime Zipper, the Chilean inventor of the quinacrine method of nonsurgical permanent contraception, was aware that when chest
surgeons injected quinacrine into the pleural cavity to treat and prevent reoccurrence of pleural effusion, it resulted in the formation of fibrous
adhesions between the lung and costal pleura. Zipper thought that a similar scarring effect could occur in the fallopian tubes if quinacrine was
instilled into the uterine cavity. A series of refinements of the methodology culminated in the use of a modified Copper T intrauterine device
inserter tube as a delivery system to introduce seven quinacrine pellets into the uterus. This approach with quinacrine sterilization (QS) was
introduced into clinical practice in several countries, and a national clinical trial of over 50,000 women was conducted in Vietnam. However,
in 1993, the World Health Organization raised concerns that quinacrine might be carcinogenic. This resulted in abandonment of QS in
Vietnam and other countries. Subsequent epidemiologic data from extensive human studies do not support an increase in cancer risk. This
paper reviews the history, limitations and clinical potential of QS.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Quinacrine; Nonsurgical; Permanent contraception; Epidemiology1. Introduction
Quinacrine was discovered, synthesized and patented in
1928 in Germany [1]. The Winthrop Pharmaceutical
Company acquired the patent. Winthrop published a
bibliography of 121 references on quinacrine in 1942 [2].
Included were human data as well as data on the use of nine
different animal species. Quinacrine is known to be safe and
effective in the treatment of a variety of parasitic infections,
including malaria, giardia and tapeworm. Quinacrine also
was effective for collagenous tissue diseases, such as lupus
erythematosus, and rheumatoid arthritis. It remains one of
the most thoroughly studied drugs of all time [3].
Where did the idea of using quinacrine as a contraceptive
originate? Quinacrine is known to be effective treating a
collapsed lung, which may be a consequence of a pleural
effusion. When the pleural fluid is drained and replaced by☆ Conflict of Interest Statement: Dr. Lippes has received no pay from any
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0010-7824/©2015TheAuthor. PublishedbyElsevier Inc.This is anopenaccess article unquinacrine, the instilled quinacrine stimulates production of
fibrous tissue causing the visceral pleura and parietal pleura
to adhere, a process known as pleurodesis [4]. Pleurodesis
eliminates the cavity in the chest, which allows the lungs to
expand, and the patient is made more comfortable. Dr. Jaime
Zipper, who first used quinacrine as a method for permanent
contraception, postulated that a similar reaction would occur,
when quinacrine was placed in the uterine cavity, and cause
sclerosis of the lumen of the human oviduct (fallopian tube).
His hypothesis turned out to be true. Dr. Zipper's initial
approach was to instill 1500 mg of quinacrine into the uterine
cavity as a slurry [5]. The 1500-mg slurry was discovered to
have significant toxicity, including at least one death. The
slurry technique was abandoned. Subsequently a refinement of
the quinacrine sterilization (QS) formulation was made.
Quinacrine was administered as seven 36-mg pellets for a
total dose of 252 mg. The pellets dissolve slowly, and
quinacrine interacts with the fallopian tube epithelium,
replacing the epithelium with fibrous tissue. This effectively
occludes the oviductal lumen [6]. Hysterectomy/Salpingectomy
specimens and pelvic sonography have identified scar tissue
(2–4 mm) in the intramural portion of the fallopian tube
following QS [6,7].der theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Subsequently QS was extensively used in developing
countries as a nonsurgical method of female sterilization.
The method offers a particular advantage in settings where
surgery is difficult to access or unsafe. Seven pellets of
quinacrine are loaded into an inserter similar to the one used
to insert the Copper T intrauterine device (IUD). The health
worker, nurse, nurse practitioner or physician deposits the
seven 36-mg pellets of quinacrine to the fundus of the uterine
cavity. Insertion of quinacrine is done at the end of menses
when quinacrine easily scleroses the lumen of the oviduct.
The insertion is repeated 4 weeks later. It is necessary to
protect the patient against pregnancy for 3 months to be
certain that the oviductal lumen is occluded. Diaphragms,
condoms and/or injected Depo-Provera are recommended
for the 3-month period.
Dr. Do Trong Hieu described the importance of technique
when inserting the pellets of quinacrine [8]. While using the
Copper T inserter, there is the expectation that as the operator
pulls back the barrel of the inserter, it leaves the pellets in a
straight line. This is known as the “Copper T IUD technique”
of insertion. Hieu found that failure or pregnancy rates were
much lower if the operator held the barrel of the inserter
steady and gently applied pressure to the push rod, thereby
depositing all pellets at the very top of the uterine cavity and
not in a straight line. This is known as the “Hieu technique”
(see Fig. 1).3. Efficacy
A pregnancy rate of 12.1% was reported by Sokal [9]. But
in that article he wrote, “…various insertion techniques may
have contributed to the relatively high failure rate.” Feldblum
reported that the cumulative 10-year pregnancy probability
for two insertions was 9%, but commented that “The varietyFig. 1. Copper T IUD technique (left) vs. Hieu technique (right) of
quinacrine intrauterine insertion for permanent contraception.of pellet regimens combined in this analysis makes it
difficult to compare pregnancy rates….” [10]. Moreover,
these failure estimates reflect the use of the Copper T IUD
technique, which was abandoned 21 years ago and replaced
by the more effective Hieu technique.
Two treatments also reduce the risk of failure. In a study
of QS sponsored by the Indonesian government to compare
single insertion versus two insertions, the pregnancy rate
within 8 years of treatment was 14.3% among 70 patients
receiving a single insertion of quinacrine, and there were
zero pregnancies among 30 women who received 2
insertions [11].
Efficacy results using the more advanced Hieu method for
placing quinacrine at the top of the uterine fundus can be
seen in Table 1. The Lu et al. paper described in Table 1
reports on a Chinese clinical trial of 589 patients that
compared pregnancy rates of 289 QS patients versus 300
women who had a surgical tubal ligation. Patients were
matched by age, parity and other variables. There were no
serious adverse events (SAEs) attributed to QS. With QS, the
cumulative life table revealed a 1.2% failure rate per 100
women at 24 months compared to 0.7% for tubal ligation
patients [12]. Further study is needed to confirm the
advantage of the Hieu technique.4. Human safety data
Quinacrine has been used extensively to treat malaria. It
was the only effective synthetic antimalarial available during
the Second World War. Three million American soldiers
took 100 mg of quinacrine daily while serving in the South
Pacific during WWII. These millions of service men and
women suffered few SAEs from quinacrine [22]. Side effects
from the chronic daily use of quinacrine include gastroin-
testinal upset and yellowing of the sclera and skin in a small
percentage of patients. Rare cases of aplastic anemia were
reported after long-term use [23]. For the treatment ofable 1
S failure rate using current protocol, i.e., employing the Hieu technique.
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93J. Lippes / Contraception 92 (2015) 91–95malaria, quinacrine was replaced by chloroquine in 1946
because it was both more effective and less toxic [24]. Before
chloroquine, in malarial endemic areas, people ingested 100
mg of quinacrine daily for many years, even as long as a
decade or more. A daily dose of 100 mg a year equals 36,500
mg/year or 365,000 mg over 10 years. By comparison, to
provide QS, the clinician installs quinacrine into the uterine
cavity in two split doses of 252 mg each, 1 month apart, for a
total lifetime dose of 504 mg. Long-term oral exposure
during World War II was associated with the development of
a cutaneous lichenoid eruption called atabrine dermatitis,
and some patients with this condition subsequently devel-
oped squamous cell carcinoma of the skin [25]. No other
evidence for human carcinogenicity exists.
In 1993, Hieu et al. reported results on 31,781 women who
had chosen QS [26]. This article, published in The Lancet,
provided evidence for the safety of quinacrine-induced tubal
sclerosis. The authors estimated that because 31,781 women
had received QS, 242 maternal deaths had been averted.
Although this study provided reassuring human safety data,
theWorld Health Organization (WHO)1 issued a statement in
1993, declaring that quinacrine should not be used for
permanent contraception. Presumably, the WHO decision
was based on a positive Ames test for mutagenicity.
However, Ames recognized that his test often gives false
positives [27]. Nevertheless, the WHO statement caused the
clinical trial of QS in Vietnam to be discontinued and
inhibited other countries from pursuing QS trials. In 1994, the
editors of The Lancet published an editorial entitled,Death of
a study, WHO, what and why, calling these actions of WHO
“reprehensible” [28].
Several epidemiology studies published between 1995
and 2012 evaluated whether QS causes cancer [29–33]. A
study of all gynecologic cancers in 12 Vietnamese provinces
during the period 2001–2006 found no increased risk with
QS [31], and similar results were seen in a separate study
from Chile [30]. When the number of individuals in each
study is small the consistency of the results of these studies
supports the conclusion of no effect of QS on cancer risk.
During this period, Dr. Claudia Ferreira and her
colleagues at Minas Gerais University Hospital in Belo
Horizonte, Brazil, made two significant contributions for
understanding and improving QS. First, they provided QS to
HIV+ women at a time when other physicians were fearful
of treating these patients [34]. Second, they performed
sonography on patients at 1-, 3-, 6- and 12-month intervals
after receiving QS. This revealed that the endometrium
returned to normal height within 2 to 4 weeks following a QS
procedure suggesting normalization of the endometrium and
no chronic inflammation [7]. Definitive evidence revealing
no chronic inflammation was provided by biopsies taken by1 Letter, Frank Webb, of the WHO Human Reproduction Programme,
to Linda Demers, UNFPA representative for Vietnam, Dec. 7, 1993.Dr. Lu in her examination of QS patients in Guizhou
Province, China [12]. These observations are important
because chronic inflammation is a known promoter of
cancer [35].
In 2000, a Food and Drug Administration (FDA) Phase 1
study of QS was initiated at the Women and Children's
Hospital of Buffalo, a teaching hospital affiliated with the
State University of New York at Buffalo School of Medicine
[36]. The hospital's investigational review board approved
the clinical trial. Ten women who desired sterilization
volunteered for QS and agreed to participate in the trial. This
study was completed in 2003. There were no SAEs reported
in this Phase 1 trial.
In October of 2003, the International Federation of
Gynecology and Obstetrics (FIGO) devoted a half-day
seminar to QS at its biannual international meeting in
Santiago, Chile. Most of the presentations were published in
a special supplemental issue of FIGO's journal, the
International Journal of Gynecology & Obstetrics [37].
Twenty-five articles from 15 countries, covering 40,252
cases of QS, updated the QS literature. This collection of
articles provides evidence for the safety of this method. All
published clinical studies to date show that QS is not
associated with an increased risk of reproductive tract cancer.
In 2001, Potts and Benagiano wrote, in an article entitled,
Quinacrine sterilization: a middle road, “…we both wish to
help broaden the range of fertility control options available,
especially for low income women around the world. .… It
always takes a decade or two to gather empiric evidence of
safety, based on large-scale actual use.” [38].5. Animal safety studies
The WHO comments on quinacrine-prompted Family
Health International to conduct animal (mouse and rat)
studies to evaluate a possible risk of cancer from QS. These
animal studies were initiated in the early 2000s. Quinacrine
demonstrated no genotoxicity in a neonatal mouse assay,
published in 2006 [39]. A 2-year rat carcinogenicity study
(CaBio) used varying doses of quinacrine, which were
placed in the rat uterus in an attempt to “mimic” the action of
QS in the human situation [40]. However, for the following
four reasons, the rat study did not mimic the human QS
experience: (a) quinacrine was administered to rats in a slurry
formulation while in women quinacrine is placed in the
uterus in the form of solid pellets (use of the slurry
formulation in women was abandoned in 1975 due to
excessive toxicity); (b) methylcellulose (MC), a known
tissue irritant that causes chronic inflammation [41], was
added to the slurry of quinacrine (MC is not part of the
quinacrine formulation administered to women); (c) the rats
developed rare cancers that were preceded by chronic
inflammation, and chronic inflammation is a known tumor
promoter in cancer induction [35] (chronic inflammation has
not been reported in women who received QS); and (d)
94 J. Lippes / Contraception 92 (2015) 91–95cancers in the rats developed only when doses of quinacrine
exceeded the maximum tolerated dose (MTD). However,
FDA/international conference on harmonization guidance
states that the MTD in a study should be one that is minimally
toxic and one that is tolerated without chronic dysfunction or
pathological changes that would interfere with the interpreta-
tion and, therefore, the validity of the study [42].
These differences in formulation and dosing undermine
the rat CaBio study's usefulness for an assessment of
carcinogenicity with QS. One published interpretation of this
rat CaBio concludes that quinacrine is not carcinogenic in
rats at doses that do not exceed the MTD [43].6. Comparison of QS to alternative methods of
permanent contraception
Some critics of QS have proffered that alternative
methods of contraception, like IUDs, might serve the same
purpose as QS. While acceptance of long-acting reversible
methods is growing in the United States, continuation rates
may be lower in developing nations. Four IUDs were
studied in a randomized controlled trial of 1905 women by
the Indian Council of Medical Research. After 3 years,
continuation of the levonorgestrel IUD was 38.8%, and the
Cu T 200 IUD ranged from 45.4% to 50.4% [44].
Sterilization is the only method where the continuation
rate approaches 100%. Essure™ (Bayer Healthcare), a
device that is placed into the openings of the fallopian tubes
using hysteroscopic guidance has been advanced as a
minimally invasive method that is safer and more effective
than traditional surgery. However, the technique still
requires surgical facilities. Considerable surgical training
is required, as failure of bilateral placement as high as 23%
have been reported [45]. This is due to various reasons,
including poor visualization, sclerosis and scarring of the
oviduct. Due to these placement problems, and failure of
some women to complete active follow up to confirm tubal
occlusion, the failure rate for hysteroscopic sterilization may
be higher than laparoscopy [46].7. Conclusion
Like all methods of family planning and especially
permanent methods, QS should always be offered in human
rights frameworks of fully informed consent. Much is now
known about QS. It is nonsurgical, there is no need for
anesthesia, and studies have shown that it is safe. With the
improved Hieu insertion technique, and two treatments, QS
effectiveness (failure rate of 1.2% after 2 years) compares
favorably, with surgical tubal ligation (0.7% at 2 years). The
cost is low, and QS can be performed by nonphysicians [12].
It is time to reexamine the epidemiological and clinical data
on the use of QS and reconsider its use in both developed and
developing countries.Acknowledgements
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